These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23557017)

  • 81. The economics of new drugs: can we afford to make progress in a common disease?
    Hirsch BR; Schulman KA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714477
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Current status and future prospects of toxicogenomics in drug discovery.
    Khan SR; Baghdasarian A; Fahlman RP; Michail K; Siraki AG
    Drug Discov Today; 2014 May; 19(5):562-78. PubMed ID: 24216320
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Drug discovery and development 2014: Returning toward the norm?
    Baldwin JJ
    Future Med Chem; 2015; 7(7):841-4. PubMed ID: 26061103
    [No Abstract]   [Full Text] [Related]  

  • 84. Industry, innovation and social values.
    Bale HE
    Sci Eng Ethics; 2005 Jan; 11(1):31-40. PubMed ID: 15726997
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Follow-on biologics: a new play for big pharma: Healthcare 2010.
    Evans I
    Yale J Biol Med; 2010 Jun; 83(2):97-100. PubMed ID: 20589191
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry.
    Song CH; Han JW
    Springerplus; 2016; 5(1):692. PubMed ID: 27347468
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The future costs, risks and rewards of drug development: the economics of pharmacogenomics.
    Cook J; Hunter G; Vernon JA
    Pharmacoeconomics; 2009; 27(5):355-63. PubMed ID: 19586074
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Impact of organ-on-a-chip technology on pharmaceutical R&D costs.
    Franzen N; van Harten WH; Retèl VP; Loskill P; van den Eijnden-van Raaij J; IJzerman M
    Drug Discov Today; 2019 Sep; 24(9):1720-1724. PubMed ID: 31185290
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Postmodern medicine: an analysis of the pharmaceutical industry and its critics.
    Ghaemi SN
    Perspect Biol Med; 2013; 56(2):223-35. PubMed ID: 23974502
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The microeconomics of personalized medicine: today's challenge and tomorrow's promise.
    Davis JC; Furstenthal L; Desai AA; Norris T; Sutaria S; Fleming E; Ma P
    Nat Rev Drug Discov; 2009 Apr; 8(4):279-86. PubMed ID: 19300459
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Drug development for neglected diseases: pharma's influence.
    Lancet; 2010 Jan; 375(9708):2. PubMed ID: 20022100
    [No Abstract]   [Full Text] [Related]  

  • 92. Clinical and Pharmaceutical Solutions through Analysis (CPSA BRASIL 2015): on the way to innovation - pharmaceutical/analytical technology, regulation and knowledge management.
    Needham S; Yates N; Barrientos R; Steel M; Lee M
    Bioanalysis; 2015 Dec; 7(23):2977-9. PubMed ID: 26617112
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Patient Centricity and Pharmaceutical Companies: Is It Feasible?
    du Plessis D; Sake JK; Halling K; Morgan J; Georgieva A; Bertelsen N
    Ther Innov Regul Sci; 2017 Jul; 51(4):460-467. PubMed ID: 30227057
    [TBL] [Abstract][Full Text] [Related]  

  • 94. 'Big data' in pharmaceutical science: challenges and opportunities.
    Dossetter AG; Ecker G; Laverty H; Overington J
    Future Med Chem; 2014 May; 6(8):857-64. PubMed ID: 24962278
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Today's challenges shape tomorrow's technology, Part 1.
    Simpson RL
    Nurs Manage; 2003 Oct; 34(10):16-9. PubMed ID: 14557775
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antibiotic resistance in the tropics. 3. Medical responsibilities of the pharmaceutical industry with respect to use of antibiotics in the tropics.
    Salter AJ
    Trans R Soc Trop Med Hyg; 1989; 83(1):45-8. PubMed ID: 2690415
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Exploiting new approaches for natural product drug discovery in the biotechnology industry.
    Gullo VP; Hughes DE
    Drug Discov Today Technol; 2005; 2(3):281-6. PubMed ID: 24981948
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Vaccine development costs: a review.
    Waye A; Jacobs P; Schryvers AB
    Expert Rev Vaccines; 2013 Dec; 12(12):1495-501. PubMed ID: 24160863
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Skunkworks project for Big Pharma.
    Palczewski K
    Pharmacol Res; 2017 Oct; 124():167-168. PubMed ID: 28363722
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.